Enzo Life Sciences
ActiveSummary
The computed 12-month bankruptcy probability of Enzo Life Sciences is 1.7% (moderate). The 2025 annual accounts show negative equity (€-1.03M) and a net result of €-186k. Equity is shrinking by ~21.1% per year across the filed fiscal years. Its solvency ranks better than 5% of 4867 sector peers (fiscal year 2025). The company has been active since 1996 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
29
/ 100
Weak
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency0=
Growth30▼-23
Track record100
Bankruptcy probability, 12 months
1.7%
Moderate
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity tight (current ratio 1.43 against 7.73 in 2024; short-term debt: 70% and cash: 21.1% of total assets), and equity is negative.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-722.6%
Return on assets
-130.2%
Age of the figures
14 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
19202122232425
2019 to 2025 · latest year €-1.03M
neutral · Latest accounts filed on time
The financial year that closed on 31-07-2025 was due by 28-02-2026 and was filed on 14-01-2026, 45 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
45 d early
2024
46 d early
2023
37 d early
2022
5 d early
2021
49 d early
2020
44 d early
2019
22 d early
← before the deadline
after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-07-2026 and is due by 28-02-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
31-07-2026 close24-09-2026 today28-02-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
€815k▼ 62.6%
2024 · €2.18M
2019: €962k
2020: €778k
2021: €1.05M
2022: €1.08M
2023: €1.33M
2024: €2.18M
2019 → 2025
EBIT margin
-22.4%▼ 16.3pp
2024 · -6.1%
2019: -6.0%
2020: -16.3%
2021: -7.3%
2022: -6.9%
2023: -10.6%
2024: -6.1%
2019 → 2025
Net result
€-186k▼ 36.4%
2024 · €-136k
2019: €-59k
2020: €-129k
2021: €-80k
2022: €-78k
2023: €-144k
2024: €-136k
2019 → 2025
Working capital
€43k▼ 90.2%
2024 · €438k
2019: €-279k
2020: €-408k
2021: €-488k
2022: €-565k
2023: €-709k
2024: €438k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Turnover€1.05M-€1.08M▲ 3.6%€1.33M▲ 22.8%€2.18M▲ 63.9%€815k▼ 62.6%
Equity€-488k-€-565k▼ 16.0%€-709k▼ 25.4%€-845k▼ 19.2%€-1.03M▼ 22.0%
Operating result€-77k-€-74k▲ 3.1%€-140k▼ 88.6%€-133k▲ 5.2%€-183k▼ 37.2%
Net result€-80k-€-78k▲ 2.3%€-144k▼ 84.3%€-136k▲ 5.2%€-186k▼ 36.4%
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €183k in 2025 against €133k in 2024; the loss grows and 2025 has the lowest result in the available series.
Key figures and ratios
Solvency
-722.6%▼
2024 · -167.9%
Current ratio
1.43▼
2024 · 7.73
Debt to equity
-1.14▲
2024 · -1.60
ROA
-130.2%▼
2024 · -27.1%
Debt
€1.17M▼
2024 · €1.35M
Debt ≤ 1 year
€100k▲
2024 · €65k
Debt > 1 year
€1.07M▼
2024 · €1.28M
Staff costs
€131k=
2024 · €131k
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 42 lines
Balance sheet
Code20242025
Assets
Total assets20/58€504k€143k▼
Current assets29/58€504k€143k▼
Amounts receivable within one year40/41€454k€113k▼
Trade receivables40€454k€112k▼
Other amounts receivable41€136€304▲
Cash at bank and in hand54/58€49k€30k▼
Equity and liabilities
Total equity and liabilities10/49€504k€143k▼
Equity10/15€-845k€-1.03M▼
Contributions10/11€19k€19k=
Reserves13€33k€33k=
Distributable reserves133€33k€33k=
Profit (loss) carried forward14€-897k€-1.08M▼
Amounts payable17/49€1.35M€1.17M▼
Amounts payable after more than one year17€1.28M€1.07M▼
Other amounts payable178/9€1.28M€1.07M▼
Amounts payable within one year42/48€65k€100k▲
Trade debts44€31k€74k▲
Suppliers440/4€31k€74k▲
Taxes, remuneration and social security45€34k€26k▼
Taxes450/3€12k€9k▼
Remuneration and social security454/9€22k€17k▼
Other amounts payable47/48€238-
Income statement
Code20242025
Operating income70/76A€2.18M€815k▼
Turnover70€2.18M€815k▼
Other operating income74-€2
Operating charges60/66A€2.31M€997k▼
Goods for resale, raw materials and consumables60€1.54M€611k▼
Purchases600/8€1.54M€611k▼
Services and other goods61€633k€254k▼
Remuneration, social security and pensions62€131k€131k=
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€7k€827▼
Other operating charges640/8€541€470▼
Operating profit (loss)9901€-133k€-183k▼
Financial charges65/66B€3k€3k▲
Recurring financial charges65€3k€3k▲
Other financial charges652/9€3k€3k▲
Profit (loss) for the period before taxes9903€-136k€-186k▼
Profit (loss) for the period9904€-136k€-186k▼
Profit (loss) for the period to be appropriated9905€-136k€-186k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-897k€-1.08M▼
Profit (loss) brought forward from the previous period14P€-761k€-897k▼
Social balance
Average headcount (FTE)90871.01.0=
The notes to these accounts (32 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
14-01
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-07
Financial
Weakest financial yearnet €-186k
Net result drops to €-186k, the lowest in the series.
13-01
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-07
Financial
Liquidity times 28current ratio 7.73
Current ratio from 0.28 to 7.73; short-term debt falls from €980k to €65k.
23-01
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
23-02
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
10-01
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
15-01
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
07-02
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
31-01
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
20-02
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
15-03
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 15 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
12 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Elsene · 1 establishment unit since 1999
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Louizalaan 651050 ElseneGround area
1,683 m²
Building footprint
2,433 m²
Volume, LiDAR
61,492 m³
Parcel 21807G0007/00R000, Brussels · tallest building 35.6 m, ±9 floors. Linked by address, not a title deed.
1 establishment unit
Enzo Life Sciences
since 19992.079.938.831
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21807G0007/00R000 | Brussels | 1,683 m² | 1 · 2,433 m² | 35.6 m · 9 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Medical Promotion
BE 0411.580.797
Jodoigne · FTE 1
OMEGA PHARMA TRADING
BE 0417.092.080
Gent · FTE 1
AMERICAN ORTHODONTICS BENELUX
BE 0422.821.911
Temse · FTE 1
bonyf
BE 0423.667.492
Knokke-Heist · FTE 1
APEX
BE 0424.131.213
Anderlecht · FTE 1
Of 1,898 companies in sector 46460 we hold annual accounts for 1,116. 460 are within a factor 10 of this headcount. The 5 above are the closest to it. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded25-11-1996
Fiscal year end31-07
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
46190Agents in non-specialised wholesale trade
46900Non-specialised wholesale trade
47789Other retail sale of new goods
95290Repair and maintenance of other personal and household goods
Sources
Crossroads Bank for EnterprisesNational Bank · 28 filingsAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.